EU Clinical Trial 2018-001461-16

A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies  Feb 13, 2019

Main objective of the trial: To determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RPTD)

Parties

Sponsors
Countries
AU CA DE EU FR IL IT US
Keywords
KEYTRUDA (pembrolizumab, MK-3475) Lymphoma malignant MK-4280 PEMBROLIZUMAB

JSON preview

Similar records

Title

Source:  EMA Last updated:  May 30, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.